文献速递病毒性肝炎

2019冠状病毒病大流行对美国丙型肝炎病毒治疗启动的持续影响

Sustained Impact of the Coronavirus Disease 2019 Pandemic on Hepatitis C Virus Treatment Initiations in the United States.
PubMed 文献 · Clin Infect Dis · 2022-01-01

研究利用2家大型国家实验室2019年1月至2020年12月的州级月度数据,分析COVID-19对HCV检测和治疗启动的影响。2020年3月至4月间HCV抗体检测、RNA检测、基因型检测和治疗启动分别下降37%、37.5%、24%和31%;2020年4月后检测有所回升,但治疗启动持续低迷。

要点

  • 2020年3月至4月HCV抗体检测下降37%(P < .001),RNA检测下降37.5%(P < .001)。
  • 同期基因型检测下降24%(P = .023),HCV治疗启动下降31%(P < .001)。
  • 2020年4月后检测回升但仅抗体检测恢复至疫情前水平,治疗启动全年未恢复。

核心结论

  • 2020年4月COVID-19大流行初期HCV检测和治疗启动下降超过30%,尽管2020年后期检测回升,但治疗率未恢复,应努力将HCV阳性患者链接至治疗并重振治疗参与。

研究设计与样本

  • 从2家大型国家实验室获取2019年1月至2020年12月按年龄和性别分层的州级月度HCV抗体、RNA和基因型检测量及治疗启动量。
  • 采用混合效应泊松回归模型进行分段回归分析,以月份为主要固定预测因子、州为随机截距。

主要发现

  • 疫情前(2019年1月至2020年3月)月度HCV抗体和基因型检测略有下降,RNA检测和治疗启动保持稳定。
  • 2020年3月至4月间HCV抗体检测下降37%(P < .001),RNA检测下降37.5%(P < .001),基因型检测下降24%(P = .023),治疗启动下降31%(P < .001)。
  • 2020年4月至2020年底,月度HCV抗体检测(P < .001)、RNA检测(P = .035)和基因型检测(P = .047)显著增加,但仅抗体检测恢复至疫情前水平。
  • 2020年4月后治疗启动在当年剩余时间持续低迷。

临床怎么用

  • 作者认为应努力将HCV阳性患者链接至治疗,并由医疗保健提供者重振HCV治疗参与。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recent reports indicated declines in hepatitis C virus (HCV) testing during the first half of 2020 in the United States due to coronavirus disease 2019 (COVID-19), but the longer-term impact on HCV testing and treatment is unclear. METHODS: We obtained monthly state-level volumes of HCV antibody, RNA and genotype testing, and HCV treatment initiation, stratified by age and gender, spanning January 2019 until December 2020 from 2 large national laboratories. We performed segmented regression analysis for each state from a mixed-effects Poisson regression model with month as the main fixed predictor and state as a random intercept. RESULTS: During the pre-COVID-19 period (January 2019-March 2020), monthly HCV antibody and genotype tests decreased slightly whereas RNA tests and treatment initiations remained stable. Between March and April 2020, there were declines in the number of HCV antibody tests (37% reduction, P < .001), RNA tests (37.5% reduction, P < .001), genotype tests (24% reduction, P = .023), and HCV treatment initiations (31%, P < .001). Starting April 2020 through the end of 2020, there were significant increases in month-to-month HCV antibody (P < .001), RNA (P = .035), and genotype tests (P = .047), but only antibody testing rebounded to pre-COVID-19 levels. HCV treatment initiations remained low after April 2020 throughout the remainder of the year. CONCLUSIONS: HCV testing and treatment dropped by >30% during April 2020 at the start of the COVID-19 pandemic, but although HCV testing increased again later in 2020, HCV treatment rates did not recover. Efforts should be made to link HCV-positive patients to treatment and revitalize HCV treatment engagement by healthcare providers.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Hoenigl M, Abramovitz D, Flores Ortega RE, et al. Sustained Impact of the Coronavirus Disease 2019 Pandemic on Hepatitis C Virus Treatment Initiations in the United States. Clin Infect Dis. 2022. PMID: 35234860. doi:10.1093/cid/ciac175

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。